Imagion Biosystems Limited previously advised that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million. To accommodate some of the excess demand, the Company had agreed to raise an additional $0.96 million on the same terms as the Offer (“Follow-On Placement”).
Imagion Biosystems receives AU$3.5 million in R&D tax incentives
September 19, 2023
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it